Shaw AT, Solomon BJ, Felip E, Bauer TM, et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study. Ann Oncol 2026 May 29:S0923-7534(26)00876-8. doi: 10.1016/j.annonc.2026.
PMID: 42217582